ArticleeLife2019
Renal medullary carcinomas depend upon
Open access · goldAbstract read
In one paragraph
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Guideline
- A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors.Cancer medicine · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.Nature reviews. Urology · 2026Review
- SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity.Nature communications · 2026Article
- Molecularly defined renal cell carcinomas.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Review
- Molecular and therapeutic landscape of non-clear cell renal carcinoma.Nature reviews. Urology · 2025Review
- Differentiating between renal medullary and clear cell renal carcinoma with a machine learning radiomics approach.The oncologist · 2025Article
- A novel case of glial transdifferentiation in renal medullary carcinoma brain metastasis.Acta neuropathologica communications · 2025Article
- The present and future of the Cancer Dependency Map.Nature reviews. Cancer · 2025Review
- SMARCB1/INI1-deficient lung cancer with lymph node metastasis: a case report and literature review.AME case reports · 2025Article
- Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies.Therapeutic advances in medical oncology · 2025Review
- Chromatin remodellers as therapeutic targets.Nature reviews. Drug discovery · 2024Review
- Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.Communications biology · 2024Article
- Article
- Children's Oncology Group's 2023 blueprint for research: Renal tumors.Pediatric blood & cancer · 2023Article
- Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas.Current issues in molecular biology · 2023Review
- SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression.The American journal of pathology · 2023Article
- SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.Cancer cell international · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 6 institutions in 1 country.
Andrew L HongBoston Children's Hospital, Boston, United States.ORCID 0000-0003-0374-1667
Yuen-Yi TsengBroad Institute of Harvard and MIT, Cambridge, United States.
Jeremiah A WalaBroad Institute of Harvard and MIT, Cambridge, United States.
Won-Jun KimDana-Farber Cancer Institute, Boston, United States.
Bryan D KynnapDana-Farber Cancer Institute, Boston, United States.
Mihir B DoshiBroad Institute of Harvard and MIT, Cambridge, United States.
Guillaume KugenerBroad Institute of Harvard and MIT, Cambridge, United States.
Gabriel J SandovalDana-Farber Cancer Institute, Boston, United States.
Thomas P HowardDana-Farber Cancer Institute, Boston, United States.
Ji LiDana-Farber Cancer Institute, Boston, United States.
Xiaoping YangBroad Institute of Harvard and MIT, Cambridge, United States.
Michelle TillgrenDana-Farber Cancer Institute, Boston, United States.
Mahmhoud GhandiBroad Institute of Harvard and MIT, Cambridge, United States.
Abeer SayeedBroad Institute of Harvard and MIT, Cambridge, United States.
Rebecca DeasyBroad Institute of Harvard and MIT, Cambridge, United States.
Abigail WardBoston Children's Hospital, Boston, United States.
Brian McSteenRare Cancer Research Foundation, Durham, United States.
Katherine M LabellaDana-Farber Cancer Institute, Boston, United States.
Paula KeskulaBroad Institute of Harvard and MIT, Cambridge, United States.
Adam TracyBroad Institute of Harvard and MIT, Cambridge, United States.
Cora ConnorRMC Support, North Charleston, United States.
Catherine M ClintonBoston Children's Hospital, Boston, United States.
Alanna J ChurchBoston Children's Hospital, Boston, United States.
Brian D CromptonBoston Children's Hospital, Boston, United States.
Katherine A JanewayBoston Children's Hospital, Boston, United States.
Barbara Van HareRare Cancer Research Foundation, Durham, United States.
David SandakRare Cancer Research Foundation, Durham, United States.
Ole GjoerupDana-Farber Cancer Institute, Boston, United States.
Pratiti BandopadhayayBoston Children's Hospital, Boston, United States.
Paul A ClemonsBroad Institute of Harvard and MIT, Cambridge, United States.
Stuart L SchreiberBroad Institute of Harvard and MIT, Cambridge, United States.
David E RootBroad Institute of Harvard and MIT, Cambridge, United States.
Prafulla C GokhaleDana-Farber Cancer Institute, Boston, United States.
Susan N ChiBoston Children's Hospital, Boston, United States.
Elizabeth A MullenBoston Children's Hospital, Boston, United States.
Charles Wm RobertsSt. Jude Children's Research Hospital, Memphis, United States.
Cigall KadochDana-Farber Cancer Institute, Boston, United States.
Rameen BeroukhimDana-Farber Cancer Institute, Boston, United States.ORCID 0000-0001-6303-3609
Keith L LigonDana-Farber Cancer Institute, Boston, United States.
Jesse S BoehmBroad Institute of Harvard and MIT, Cambridge, United States.ORCID 0000-0002-6795-6336
William C HahnDana-Farber Cancer Institute, Boston, United States.ORCID 0000-0003-2840-9791
Broad Institute · USDana-Farber Cancer Institute · USBoston Children's Hospital · USCancer Research Foundation · USCharleston Area Medical Center · USSt. Jude Children's Research Hospital · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MMolecular, Cellular, & Developmental Dynamics PhD ProgramT32GM007226 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI VAN VACTOR, DAVID L. · 1985 to 2021
$14.4MThe Child Heath Research CenterK12HD052896 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Wendy K Chung · 2007 to 2026
$7.9MResearch Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MTargeting vulnerabilities of therapy-resistant cancer cell states with small moleculesU01CA217848 · NCI · BROAD INSTITUTE, INC. · PI SCHREIBER, STUART L · 2017 to 2021
$5.8MTargeting FAK and integrin signaling in preclinical models of Ewing sarcomaK08CA188073 · NCI · DANA-FARBER CANCER INST · PI CROMPTON, BRIAN · 2015 to 2019
$886kAlex's Lemonade Stand Foundation for Childhood Cancer Young Investigator AwardAmerican Association for Cancer Research 14-40-31-HONGAmerican Cancer Society 132943-MRSG-18-202-01-TBGBoston Children's Hospital OFD BTREC CDACureSearch for Children's Cancer 328545Dana-Farber Cancer Institute Wong Family AwardNCI NIH HHS K08 CA188073NCI NIH HHS P50 CA101942NCI NIH HHS T32 CA136432NCI NIH HHS U01 CA176058NCI NIH HHS U01 CA217848NHGRI NIH HHS T32 HG002295NICHD NIH HHS K12 HD052896NIGMS NIH HHS T32 GM007226NIGMS NIH HHS T32 GM007753U.S. Department of Defense W81XWH-15-1-0659
Abstract
Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic fusion events in one
Indexed as
AllelesAnimalsCarcinoma, MedullaryCell CycleCell Line, TumorCRISPR-Cas SystemsExomeFemaleHumansIn Situ Hybridization, FluorescenceKidneyKidney NeoplasmsMiceMice, NudeMutationNeoplasm TransplantationProteasome Endopeptidase ComplexProteasome InhibitorsSMARCB1 ProteinSMARCB1 protein, humanUbiquitincancer biologycell cyclehumanhuman biologymedicineMLN2238renal medullary carcinomaSMARCB1ubiquitin-proteasome system
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.